30 closest matches · ranked by relevance
Cystic Fibrosis · Chronic Pancreatitis
Primary: Mean Change in Total Symptom Score (TSS) From Day 1 (Baseline) to Days 8, 15, 29, and 85 — 0.0012; 0.0480; 0.1506; 0.0791 score on a scale
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percentage of Participants Who Were Responders After 1 Week of Treatment With Study Medication — 68.4 percentage of participants
Chronic Pancreatitis · Pancreatectomy · Pancreatic Exocrine Insufficiency
Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001
Exocrine Pancreatic Insufficiency · Steatorrhea · Malabsorption Syndromes
Primary: Change in the Coefficient of Fat Absorption (COA-fat Percent) — -34.1; -1.5 percentage COA-fat — p=<0.001
Chronic Pancreatitis · Exocrine Pancreatic Insufficiency
Primary: Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008 — 88.87; 89.86 percent CFA — p=0.228
Exocrine Pancreatic Insufficiency (EPI) · Cystic Fibrosis (CF)
Primary: Efficacy of MS1819-SD: Coefficient of Fat Absorption (CFA) — 55.6; 86.2 % CFA
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percent Coefficient of Fat Absorption (CFA%) — 88.28; 62.76 percent CFA — p=<0.001
Type 1 Diabetes
Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43
Cystic Fibrosis
Primary: Coefficient of Fat Absorption (%) — 88.62; 49.78 Percentage — p=<0.001
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Percent Coefficient of Fat Absorption (CFA) — 78.27; 80.35 percent CFA — p=0.4590
Exocrine Pancreatic Insufficiency · Chronic Pancreatitis · Pancreatectomy
Primary: Percent Coefficient of Fat Absorption (CFA) — 85.52; 58.02 percent CFA — p=<0.0001
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Percent Coefficient of Fat Absorption (CFA) — 88.55; 55.61 Percent CFA — p=<0.0001
Diabetes Mellitus, Type 2 · Exocrine Pancreatic Insufficiency
Primary: Part A: Serum TG Level. — 2.07; 1.68; 2.00 millimole per litre (mmol/L)
Pancreatic Insufficiency · Cystic Fibrosis
Primary: Coefficient of Fat Absorption — 80; 77 % fat absorption
Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Coefficient of Fat Absorption (%) — 47.41; 82.81 Percentage — p=<0.001
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety of Adrulipase — 2 Participants
Cystic Fibrosis · Exocrine Pancreatic Insufficiency · Pancreatic Diseases
Primary: Number of Patients With Adverse Drug Reaction — 1 participants
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants
Cystic Fibrosis
Primary: Part 1 Coefficient of Fat Absorption (CFA) — 85.53; 84.59 percentage of fat intake absorbed
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Exocrine Pancreatic Insufficiency · Pancreatic Diseases · Digestive System Diseases
Primary: Number of Patients With Adverse Drug Reaction — 36 participants
Exocrine Pancreatic Insufficiency (EPI) · Cystic Fibrosis (CF)
Primary: Safety of MS1819 by Number of Subjects Reporting 1 or More Adverse Events — 1; 0; 2; 0 Participants
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 71.0; 70.9; 71.8; 75.9 percentage of fat intake
Obesity
Primary: Fat Absorption — 60.6 g/d — p=<0.05
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety — 3; 0 Participants
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Treatment Difference for Acceptability of Treatment — 1.5; 3.5; 2.5; 1.0 units on a scale
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Treatment Difference in Coefficient of Fat Absorption (CFA) Change From Baseline — -11.852 percent change from baseline
Cystic Fibrosis · Exocrine Pancreatic Insufficiency
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 3; 10; 4 participants